Sponsor of Module 2: Investigation & Diagnosis About Enalees Enalees is an international biotechnology company specialised in rapid molecular diagnostics for animal health. The company develops, manufactures and markets LAMP-based isothermal PCR tests that enable veterinary professionals to investigate suspected infectious diseases directly in the clinic or in the field, without routinely depending on external laboratory pathways. Its diagnostic ranges…
Supportive care: treating FIP is more than just antivirals Overview Presenters Dr Samantha Taylor BVetMed(Hons) PhD CertSAM DipECVIM-CA MANZCVS FRCVS
By the end of this lecture, participants will be able to:
Describe the epidemiology, transmission, and shedding patterns of feline coronavirus in multi-cat environments.
Interpret FCoV diagnostic tests and understand their strengths and limitations in clinical practice.
Identify evidence-based strategies to reduce FCoV transmission in multi-cat households and breeding catteries.
Develop practical recommendations for breeders and shelters regarding infection control, kitten management, and FIP risk reduction.
By the end of this webinar, participants should be able to:
Compare compounded antiviral drugs to unlicensed “black market” formulations, and explain the risks of unlicensed products
Identify the legal status of compounded antivirals in my country, and know where to go to find updates
Explain factors contributing to the ongoing use of unlicensed formulations globally
Understand the importance of veterinary continuing education on this topic, and where to direct my colleagues who are not yet informed about FIP therapy
Recognize the critical importance of stocking antiviral drugs in my hospital (where legally allowable)
By the end of this lecture, participants will be able to:
1. Recognize atypical and complicated presentations of feline infectious peritonitis, including concurrent sepsis, IMHA and infectious co-morbidities.
2. Recognize complicated FIP cases that may not look like FIP on the first sight
3. Develop diagnostic plans to distinguish FIP progression from secondary complications or concurrent diseases.
4. Formulate evidence-informed treatment strategies that integrate antiviral therapy with management of immune-mediated, and infectious complications.
By the end of this webinar, participants should be able to:
Describe the currently recognised long-term clinical, laboratory, and imaging findings in cats following successful antiviral treatment of FIP.
Differentiate residual post-FIP abnormalities from true FIP relapse and recognise that persistent or newly developing abnormalities after successful treatment do not necessarily indicate FIP.
Recognise newly emerging diseases in FIP survivors, including lymphoma, and incorporate appropriate differential diagnoses when cats develop clinical signs following successful FIP treatment.
Develop a rational approach to long-term follow-up of FIP survivors, including appropriate investigation of persistent or new abnormalities.
Treating neurological FIP: overcoming challenges Overview Presenters Dr Samantha Taylor BVetMed(Hons) PhD CertSAM DipECVIM-CA MANZCVS FRCVS
By the end of this lecture, participants will be able to:
Understand current working definitions including treatment failure and re-emergent FIP
Explain why “re-emergent FIP” is preferred over relapse vs reinfection in most clinical settings
Understand the pros and cons of repeating re-treatment too soon
Describe practical retreatment approaches based on prior response and current disease presentation